

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUTCHMED (China) Limited
和黃醫藥（中國）有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 13)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached announcement which has been published by HUTCHMED (China) Limited on the website of the U.K. Regulatory Information Service on October 21, 2024.

By Order of the Board

Edith Shih

Non-executive Director and Company Secretary

Hong Kong, October 21, 2024

As at the date of this announcement, the Directors of the Company are:

Chairman and Non-executive Director:

Dr Dan ELDAR

Executive Directors:

Dr Weiguo SU

*(Chief Executive Officer and
Chief Scientific Officer)*

Mr CHENG Chig Fung, Johnny

(Chief Financial Officer)

Non-executive Directors:

Ms Edith SHIH

Ms Ling YANG

Independent Non-executive Directors:

Mr Paul Rutherford CARTER

(Senior Independent Director)

Dr Renu BHATIA

Mr Graeme Allan JACK

Professor MOK Shu Kam, Tony

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ — Monday, October 21, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on October 20, 2021 to the following persons discharging managerial responsibilities were vested on October 20, 2024:-

Award Holder	Number of American depositary shares (“ADS”)
Dr Dan Eldar (Non-executive Director (“NED”))	1,938
Ms Edith Shih (NED)	1,938 ⁽¹⁾
Mr Paul Carter (Independent Non-executive Director (“INED”))	1,647 ⁽²⁾
Mr Graeme Jack (INED)	1,938
Professor Tony Mok (INED)	1,938

Notes:

- (1) These ADSs were not received by Ms Edith Shih, but were received by or for the account of her employer, Hutchison International Limited.
- (2) Mr Paul Carter elected, on acceptance of the grant of his awards, to have 15% of his LTIP awards (amounting to US\$9,375 with respect to his awards which vested on October 20, 2024) held on his behalf by the trustee administering the LTIP pending vesting in the form of cash, to settle his tax liabilities in respect of his awards.
- (3) Since the vesting date is not a trading day, the relevant ADSs are scheduled to be transferred to the award holders on October 21, 2024.

The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

(a) Dr Dan Eldar

1 Details of the person discharging managerial responsibilities/person closely associated	
a) Name	Dr Dan Eldar
2 Reason for the notification	
a) Position/status	Non-Executive Director
b) Initial notification/Amendment	Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	HUTCHMED (China) Limited
b) LEI	2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a) Description of the financial instrument, type of instrument	ADS each representing five Ordinary Shares of US\$0.10
Identification code	ADS ISIN: US44842L1035
b) Nature of the transaction	Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP

c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Nil</td> <td>1,938 ADS</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Nil	1,938 ADS
Price(s)	Volume(s)					
Nil	1,938 ADS					
d)	Aggregated information — Aggregated volume — Price	N/A				
e)	Date of the transaction	2024-10-20				
f)	Place of the transaction	Outside a trading venue				

(b) Mr Paul Carter

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name	Mr Paul Carter				
2	Reason for the notification					
a)	Position/status	Independent Non-Executive Director				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	HUTCHMED (China) Limited				
b)	LEI	2138006X34YDQ6OBYE79				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument	ADS each representing five Ordinary Shares of US\$0.10				
	Identification code	ADS ISIN: US44842L1035				
b)	Nature of the transaction	Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Nil</td> <td>1,647 ADS</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Nil	1,647 ADS
Price(s)	Volume(s)					
Nil	1,647 ADS					
d)	Aggregated information — Aggregated volume — Price	N/A				
e)	Date of the transaction	2024-10-20				
f)	Place of the transaction	Outside a trading venue				

(c) Mr Graeme Jack

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Mr Graeme Jack
2	Reason for the notification	
a)	Position/status	Independent Non-Executive Director

b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	HUTCHMED (China) Limited				
b)	LEI	2138006X34YDQ6OBYE79				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	ADS each representing five Ordinary Shares of US\$0.10 ADS ISIN: US44842L1035				
b)	Nature of the transaction	Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Nil</td> <td>1,938 ADS</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Nil	1,938 ADS
Price(s)	Volume(s)					
Nil	1,938 ADS					
d)	Aggregated information — Aggregated volume — Price	N/A				
e)	Date of the transaction	2024-10-20				
f)	Place of the transaction	Outside a trading venue				

(d) Professor Tony Mok

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Professor Tony Mok
2	Reason for the notification	
a)	Position/status	Independent Non-Executive Director
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	HUTCHMED (China) Limited
b)	LEI	2138006X34YDQ6OBYE79
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	ADS each representing five Ordinary Shares of US\$0.10 ADS ISIN: US44842L1035
b)	Nature of the transaction	Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP

c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	1,938 ADS
d)	Aggregated information — Aggregated volume — Price	N/A	
e)	Date of the transaction	2024-10-20	
f)	Place of the transaction	Outside a trading venue	

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the US and Europe. For more information, please visit: www.hutch-med.com or follow us on [LinkedIn](#).

CONTACTS

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com

Media Enquiries

Ben Atwell / Alex Shaw,
FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) /
HUTCHMED@fticonsulting.com

Zhou Yi, Brunswick

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Nominated Advisor

Atholl Tweedie / Freddy Crossley / Rupert Dearden, +44 (20) 7886 2500
Panmure Liberum